ADC Strategy Is Shifting, Here’s What ASCO 2026 Revealed

ADC development is shifting fast, with immunotherapy now dominating combination strategies in solid tumours, accounting for 74% of approaches reported at ASCO 2026.

From earlier-line use to more advanced combination approaches, ASCO 2026 highlights a rapidly evolving ADC landscape, and the teams who act on these insights early will be best positioned to stay ahead.

Get a clear, expert-led view of the trends shaping ADC development

ASCO 2026 confirmed what many in the industry have been anticipating: ADCs are no longer confined to late-line settings, they’re rapidly becoming foundational therapies across frontline and combination strategies.

In this report, our analysts distil the most important clinical updates, competitive shifts, and emerging opportunities – helping R&D, CI, and strategy teams cut through the noise and focus on what matters most.


Download the report to explore:
  • The shift to earlier-line use as validated targets like HER2 and TROP2 move into frontline and perioperative settings
  • How combination strategies are evolving, with immunotherapy dominating and next-gen bispecific approaches emerging
  • Where competition is heating up, including growing activity in Nectin-4 and topo I-based ADCs
  • The indications to watch, with breast and gastric cancers leading frontline innovation, and key breakthroughs emerging in lung cancer
  • Curated summaries of frontline combination therapies, organized by tumour type for easy navigation
ADC ASCO Highlights

You May Also Be Interested In…

Learn More About ADC

What is Beacon ADC?
  • The Most Comprehensive Way to Search the ADC Drug Development Landscape: Unique search ontologies based on ADC drug and trial characteristics
  • Market Leading Approach to ADC Preclinical & Clinical Data Curation: Manual curation of key ADC research and development data points by ADC research scientists
  • Seamlessly Integrate Commercial & Scientific Data all in One Place: Search ADC company and deal data based on their pipeline and technologies.
  • Unrivalled Granularity in Reports & Analysis: Our search ontology and technology indexing enable comprehensive analysis not seen elsewhere.
Learn More About Beacon ADC Request Demo

What is Beacon?

Beacon is the essential intelligence platform for R&D decision-makers working in pharma and biotech, offering unique technology and drug datasets for complex therapeutics and disease areas.

Our market-defining proprietary ontologies, manual data curation, and accurate and comprehensive life science data, provide our customers with unparalleled visibility of the drug, trial and commercial landscape.

This is why 24 of the top 25 pharmaceutical companies trust Beacon to power their critical pipeline, competitive, and commercial decisions.

We’d welcome the opportunity to show you how Beacon can transform your data strategy. Book your personalized demonstration today!

Request Demonstration

Menu
Search Icon
Close Icon
Search